Quick Takeaways
- WASATCH ADVISORS LP filed SCHEDULE 13G/A for C4 Therapeutics, Inc. Common Stock (CCCC).
- Disclosed ownership: 10%.
- Date of event: 30 Apr 2025.
WASATCH ADVISORS LP - 30 Apr 2025 SCHEDULE 13G/A Report for C4 Therapeutics, Inc. Common Stock (CCCC)
- Filing Manager
- WASATCH ADVISORS LP
- Reporting Manager
- WASATCH ADVISORS LP
- Security
- C4 Therapeutics, Inc. Common Stock
- Symbol
- CCCC
- Shares outstanding
- 71,174,590 shares
- Disclosed Ownership
- 7,473,332 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 May 2025, 13:39:49 UTC
- Date of event
- 30 Apr 2025
- Next filing
- 13 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"WASATCH ADVISORS LP disclosed 10% ownership in C4 Therapeutics, Inc. Common Stock (CCCC) on 30 Apr 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 May 2025, 13:39.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 10% | 7,473,332 | 6,754,534 | 0 | Mike Yeates | CEO |